[HTML][HTML] Attenuation of the transforming growth factor β-signaling pathway in chronic venous ulcers

I Pastar, O Stojadinovic, A Krzyzanowska… - Molecular …, 2010 - Springer
I Pastar, O Stojadinovic, A Krzyzanowska, S Barrientos, C Stuelten, K Zimmerman…
Molecular medicine, 2010Springer
Transforming growth factor β (TGFβ) is important in inflammation, angiogenesis,
reepithelialization and connective tissue regeneration during wound healing. We analyzed
components of TGFβ signaling pathway in biopsies from 10 patients with nonhealing venous
ulcers (VUs). Using comparative genomics of transcriptional profiles of VUs and TGFβ-
treated keratinocytes, we found deregulation of TGFβ target genes in VUs. Using
quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis, we …
Abstract
Transforming growth factor β (TGFβ) is important in inflammation, angiogenesis, reepithelialization and connective tissue regeneration during wound healing. We analyzed components of TGFβ signaling pathway in biopsies from 10 patients with nonhealing venous ulcers (VUs). Using comparative genomics of transcriptional profiles of VUs and TGFβ-treated keratinocytes, we found deregulation of TGFβ target genes in VUs. Using quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis, we found suppression of TGFβRI, TGFβRII and TGFβRIII, and complete absence of phosphorylated Smad2 (pSmad2) in VU epidermis. In contrast, pSmad2 was induced in the cells of the migrating epithelial tongue of acute wounds. TGFβ-inducible transcription factors (GADD45β, ATF3 and ZFP36L1) were suppressed in VUs. Likewise, genes suppressed by TGFβ (FABP5, CSTA and S100A8) were induced in nonhealing VUs. An inhibitor of Smad signaling, Smad7 was also downregulated in VUs. We conclude that TGFβ signaling is functionally blocked in VUs by downregulation of TGFβ receptors and attenuation of Smad signaling resulting in deregulation of TGFβ target genes and consequent hyperproliferation. These data suggest that application of exogenous TGFβ may not be a beneficial treatment for VUs.
Springer